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Abstract
Cholangiocarcinoma (CCA) is a disease with a very poor prognosis and limited treatment options. Although 
targeted therapies directed towards specific mutations found in CCA are becoming available and are showing 
great potential, many tumors do not carry actionable mutations and, in those that do, the emergence of 
drug resistance is a likely consequence of treatment. Therapeutic targeting of enzymes and other proteins 
that show elevated activity in CCA cells but which are not altered by mutation is a potential strategy for the 
treatment of target negative and drug-resistant disease. Protein kinase CK2 (CK2) is a ubiquitously expressed 
kinase that has increased expression and increased activity in a variety of cancer types including CCA. Several 
potent CK2 inhibitors are in pre-clinical development or under assessment in a variety of clinical trials often 
in combination with drugs that induce DNA damage. This review outlines the importance of CK2 in CCA and 
assesses the progress that has been made in the evaluation of CK2 inhibition as a treatment strategy in this 
disease. Targeting CK2 based on the expression levels or activity of this protein and/or in combination with 
drugs that induce DNA damage or inhibit cell cycle progression, could be a viable option for tumors that lack 
actionable mutations, or for tumors that develop resistance to targeted treatments.
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Cholangiocarcinoma
Cholangiocarcinoma (CCA) accounts for around 15% of primary liver cancers and this disease has both 
increasing incidence and increasing mortality (reviewed in [1]). In most geographical regions, CCA is a 
relatively rare cancer with an incidence of less than 6/100,000 of the population [1]. However, in Southeast 
Asia, the incidence of this disease is much higher due to widespread liver fluke infection and Opisthorchis 
viverrine and Clonorchis sinensis are recognized causative agents of this disease [2]. In Thailand alone, liver 
fluke-induced CCA results in around 20,000 deaths per year and in the wider region, this disease is a major 
challenge to health care systems and a significant barrier to economic development [3, 4]. Additional risk 
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factors for CCA include cholestasis (loss of bile flow), exposure to dietary toxins and alcohol consumption, 
chronic hepatitis B or hepatitis C infection, and autoimmune-related diseases such as primary sclerosing 
cholangitis [1]. In all regions, CCA is usually advanced at presentation and the prognosis for newly diagnosed 
patients is often bleak. In general, only 30% of newly diagnosed patients are suitable for surgical resection 
and, for patients who undergo surgery, five-year survival is only around 50% [5, 6]. For patients with the 
non-resectable disease, the prognosis is even worse with overall survival of only around 1 year [7]. In 
Southeast Asia, the prognosis for newly diagnoses patients is dire. In Thailand, for example, only around 
2% of patients with intrahepatic CCA are eligible for surgical resection and the five-year survival for these 
patients is only around 20% while for non-resectable disease the median overall survival is just 2 months [3]. 
The rising incidence of this disease and the very poor outlook for patients make this a global health problem 
that requires new methods for earlier diagnosis as well as new treatment approaches.
CCA can be divided into distinct disease types based on anatomical location; intrahepatic CCA is located 
in the bile ductules and represents about 15% of cases, while extrahepatic CCA comprises perihilar CCA, 
located in the left and right hepatic ducts as they join and emerge from the liver and representing about 
55% of cases, and distal CCA, located in the common bile duct and representing around 30% of cases [1]. 
Genomic sequencing has shown that intrahepatic CCA often displays an increased frequency of mutations 
in genes encoding isocitrate dehydrogenase (IDH, IDH1, IDH2) and Kirsten rat sarcoma 2 viral oncogene 
homolog (KRAS), fibroblast growth factor receptor (FGFR) 2 gene fusion events, and tumour protein 
p53 (TP53) mutations whereas extrahepatic CCA often shows an increased frequency of mutations in KRAS and 
TP53 [8, 9]. In addition, liver fluke-associated CCA and non-liver fluke-associated CCA appear to have different 
mutational profiles; liver fluke-associated CCA displays a higher frequency of erb-b2 receptor tyrosine kinase 
2 (ERBB2) gene amplification and TP53, and SMAD family member 4 (SMAD4) mutations, and fluke-negative 
CCA display programmed cell death 1 ligand 1 (PD-L1)/programmed cell death 1 ligand 2 (PD-L2) protein 
expression, mutations in IDH1/2 and breast-cancer susceptibility gene 1-associated protein 1 (BAP1), and 
FGFR-related gene rearrangements [8, 10, 11]. These differences in mutational profiles may be related to 
the different aetiology of these disease states including the immune response and the relative importance of 
different disease co-factors such as dietary components [1].
CCA is characterized by a tumor stroma that promotes aggressive tumor behavior through paracrine 
signaling and this offers opportunities for new drug treatments [12-14]. Cancer-associated fibroblasts (CAFs) 
derived from local fibroblasts (hepatic stellate cells, HSCs) or bone marrow-derived mesenchymal stem 
cells (MSCs) are stromal cells that become activated in response to signals from CCA cells and through 
interaction with other stroma cells [15, 16]. Tumor-associated neutrophils and macrophages are associated 
with poor prognosis in a variety of cancer types [17] and a risk signature based on the presence of 
tumor-associated neutrophils and FOXP3+ regulatory T cells (Tregs) in extrahepatic CCA has been 
identified [18]. CD4+ Tregs are also associated with poor prognosis and can suppress host immune responses 
and promote tumor growth and invasion [19]. Multiple other cell types in the tumor stroma, including blood 
platelets, T helper cells [Th, responsible for immune surveillance such as interleukin-17 (IL17)-producing 
T cells (Th17 cells) associated with autoimmunity], and Tregs (that inhibit the activity of Th cells) produce 
transforming growth factor (TGF) β and other factors that act on the CCA cells [20]. TGFβ also acts on the 
immune cells favoring the development of Tregs and enabling the evasion of immune responses by, for example, 
prostate cancer cells [21].
Current treatments
Current treatment options for CCA have been recently reviewed [1, 5, 22] and here we will only briefly 
summarise this topic. Surgical resection of CCA offers the potential of curative treatment. This can be followed 
by adjuvant chemotherapy with capecitabine, a pro-drug which following conversion to 5-fluorouracil, blocks 
DNA replication by acting as an inhibitor of thymidylate synthase [23]. Liver transplantation is also potentially 
curative for intrahepatic and perihilar CCA but this is not widely available or likely to become so in the near 
future. For non-resectable diseases, the first-line treatment is cisplatin and gemcitabine [7, 22, 24]. Cisplatin 
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induces DNA damage in the form of intrastrand diadducts, and interstrand cross-links which can block DNA 
replication and initiate cell death via apoptosis. Similarly, gemcitabine inhibits DNA replication and induces 
apoptosis. Following disease progression, 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) is a second-line 
treatment [25]. Leucovorin increases inhibition of thymidylate synthase by 5-fluorouracil resulting in more 
effective inhibition of DNA replication while oxaliplatin induces DNA damage and blocks DNA replication. 
None of these treatments specifically target cancer cells and in all cases, drug-resistant cells can emerge 
through, for example, the up-regulation of DNA damage repair processes [1]. Moreover, 5-year survival is only 
around 50% for resectable disease and the prognosis for the non-resectable disease is much worse [5-7]. For 
these reasons, new treatments modalities are urgently needed.
New treatment opportunities
Immunotherapy has shown promise in the treatment of CCA [26]. Blocking the interaction between the 
PD-1 protein expressed on T cells, and the PD-L1, PD-L2 proteins expressed on cancer cells can result in the 
activation of intrinsic T cell cytotoxicity and cancer cell killing. CCA cells commonly express PD-L1 and PD-1 
expressing lymphocytes infiltrate CCA tumors [27, 28]. PD-L2 expression is also seen in some CCA cells. The 
anti-PD-1 antibody pembrolizumab has shown promising results in the treatment of CCA [29, 30]. However, 
early data indicates that only around 40% of patients might respond positively to this treatment. This 
approach will need to be improved if it is to benefit the majority of patients and this could be done by new 
immunotherapy-drug combinations and/or new immunotherapies that restore immune surveillance [31, 32].
Heparin-binding growth factors (HB-GFs), including vascular endothelial growth factors (VEGFs) and 
platelet-derived growth factors (PDGFs) released from stromal cells, support tumor growth and progression 
to a more aggressive, invasive phenotype and CCA cells produce and respond differently to HB-GFs 
through aberrant receptor/co-receptor expression/activity [12]. However, the inhibition of angiogenesis 
using bevacizumab to target VEGF-A, or sorafenib to block VEGF receptor activity, has not proven to be a 
highly effective treatment for CCA in clinical trials [33, 34] and lymphangiogenesis inhibition, using PDGF 
receptor (PDGFR) inhibitors or VEGF-C/VEGF receptor (VEGFR) 3 inhibitors has promise but has not yet 
been tested in clinical trials [35]. Blood platelets are commonly found in tumors and act as a source of PDGF 
and other growth factors including TGFβ. PDGF has been shown to increase CCA cell invasion [36] and to 
increase VEGF-C and VEGF-A production by tumor-associated fibroblasts [35]. Blocking the activity of PDGF 
and other growth factors released by blood platelets could also be of value in the treatment of CCA and further 
work is needed in this area.
Several recent studies have characterized the mutational landscape in CCA cells and identified 
mutations that can be targeted and these approaches have recently been reviewed in detail [1]. For example, 
sequencing of tumor DNA can identify targetable mutations such as gene fusion events that involve the 
FGFR2 gene [37, 38]. FGFR2 fusions are found in around 10% of CCA can be targeted by kinase inhibitors 
such as pemigatinib and infigratinib [39]. In 2020, the United States Food and Drug Administration granted 
approval for the use of pemigatinib in the treatment of CCA patients with FGFR2 gene fusions. However, many 
if not most CCA tumors lack mutations that are currently targetable, and moreover, resistance to targeted 
therapies are quick to emerge. One possible approach in these cases is to target enzymes and other proteins 
that are expressed at higher levels in tumor cells than in normal cells. This is known as dose-dependent 
synthetic lethality. For example, aberrant expression of the proline rich homeodomain protein (PRH)/
haematopoietically expressed homeobox (HHEX) transcription factor in CCA cells results in increased 
cyclin-dependent kinase (CDK) 4/6 activity and a consequent increase in sensitivity to the CDK4/6 inhibitor 
palbociclib [40]. This approach can also be used against targets such as growth factors that are functional in 
the tumor microenvironment rather than in the tumor cells.
Protein kinase CK2
Protein kinase CK2 (CK2, formerly known as casein kinase 2) is a serine/threonine kinase that 
phosphorylates a range of intracellular and extracellular target proteins that are important in many 
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biological processes including cell proliferation, cell migration, and invasion, all key elements of the cancer 
cell phenotype. Excellent comprehensive reviews of CK2 structure and function are available [41-43] and 
here we will only briefly introduce CK2 before reviewing its relevance in CCA and cellular processes relevant 
to this disease and its treatment.
CK2 is a hetero-tetrameric protein with two catalytic α subunits and two regulatory β subunits. There 
are two highly related CK2 α isoenzymes encoded by the CSNK2A1 and CSNK2A2 genes while there is a single 
form of the regulatory β subunit, encoded by the CSNK2B gene. CK2 is a constitutively active protein kinase 
that transfers a phosphate from adenosine triphosphate (ATP) or guanosine triphosphate (GTP) to serine or 
threonine residues in target proteins in sites corresponding to the consensus sequence S/T–X–X–D/E where 
X can be any amino acid or S/T–X–X–pS where pS represents phospho-serine [44, 45]. The later sequence 
allows the regulation of phosphorylation by CK2 by other kinases. In some cases, CK2 can phosphorylate 
tyrosine residues although this is a much rarer event. Some CK2 target proteins bind to the regulatory CK2 β 
subunit and this can increase or decrease target phosphorylation by the CK2 α subunits [46]. Many signaling 
pathways alter CK2 activity through either (i) direct effects on CK2 enzymatic activity, (ii) the creation of 
sites for CK2 phosphorylation by other phosphorylation events, (iii) transcriptional regulation of the 
genes encoding CK2 subunits, (iv) the alteration of CK2 intracellular localization, (v) changes in regulatory 
interactions with the β subunit, or possibly though (vi) β subunit phosphorylation [42]. Increased CK2 activity 
results in the up-regulation of cell proliferation via multiple mechanisms including, for example, increased 
phosphorylation of the PRH/HHEX transcription factor in vascular smooth muscle cells [47].
CK2 and cell signaling pathways
CK2 is important in multiple signal transduction pathways and many of these pathways regulate CK2 
activity (reviewed in [42]). This creates regulatory feedback loops many of which are poorly understood. 
A full description of the interactions between these signaling pathways and CK2 is beyond the scope of this 
review. However, several growth factor receptor tyrosine kinases including PDGFR and epidermal growth 
factor receptor (EGFR), activate Src family tyrosine kinases which in turn activate mitogen-activated 
protein kinase (MAPK) and other kinases important in signal transduction including CK2. For example, 
Lyn and c-Fgr are Src family tyrosine kinases that up-regulate CK2 activity through the phosphorylation 
of CK2 α subunits [48]. The inhibition of Src activity using drugs such as dasatinib results in the indirect 
inhibition of CK2 [49, 50]. CK2 is also important in inflammatory responses and other signaling pathways 
that involve nuclear factor-kappa B (NF-κB) since CK2 phosphorylates inhibitor of NF-κB (IκB) triggering 
NF-κB activation [51].
CK2 in DNA repair
CK2 is important in many aspects of the cellular response to DNA damage and the consequent DNA repair 
processes. Several proteins important in the DNA damage response or DNA repair are CK2 substrates. The 
p53 tumor suppressor protein (TP53) for example can induce cell cycle arrest or apoptosis in response to 
DNA damage and phosphorylation of p53 by CK2 required for p53 function [52-54]. However, CK2 can also 
interact with substrate proteins and non-substrate proteins involved in DNA repair possibly in order to 
recruit CK2 to specific sites. p53 is a case in point since p53 interacts with the CK2 regulatory subunit as well 
as being a CK2 substrate [53, 55]. A recent comprehensive review of these interactions and the role of CK2 in 
DNA damage and DNA repair is available [56] and here we will focus on the importance of CK2 in the repair 
of DNA damage induced by chemotherapeutic drugs such as cisplatin.
DNA damage results in the formation of DNA repair foci characterized by the accumulation of 
phosphorylated histone variant H2AX (γH2AX) which in turn recruits the Mre11-Rad50-Nbs1 (MRN) 
complex to initiate repair. Ataxia-telangiectasia mutated (ATM) kinase is primarily responsible for the 
phosphorylation of H2AX in response to DNA damage [57]. However, CK2 colocalizes with H2AX in DNA 
repair foci, and the inhibition of CK2 delays the clearance of these foci suggesting that CK2 activity is required 
for the completion of DNA repair and/or foci disassembly [58]. Cisplatin-induced DNA damage recruits x-ray 
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repair cross-complementing 1 (XRCC1) which in turn recruits multiple DNA repair proteins. XRCC1 is a CK2 
substrate and CK2-dependent phosphorylation is required for the incorporation of phosphorylated XRCC1 
into DNA repair foci [59]. Inhibition of CK2 reduces the phosphorylation of XRCC1 in response to cisplatin 
treatment resulting in increased apoptotic cell death in ovarian carcinoma cell lines and reduced tumor 
growth in mouse xenograft cancer models [60]. Similar results were seen when combining CK2 inhibition 
with gemcitabine treatment which also induces phosphorylation of XRCC1 [60]. The combination of CK2 
inhibition with cisplatin or gemcitabine also increased the levels of γH2AX in these cells [60].
CK2 expression and activity in cancer cells
The genes encoding CK2 subunits are not commonly mutated in cancer cells; CSNK2A1, CSNK2A2, and 
CSNK2B are mutated in around 2%, 1%, and 1%, respectively, of 10,967 patient samples from 32 studies in The 
Cancer Genome Atlas (TCGA; https://www.cancer.gov/tcga). CSNK2A1 is amplified in some cancers albeit 
at a relatively low frequency. However, over-expression of CK2 α in conjunction with the Myc proto-oncogene 
protein can bring about acute lymphocytic leukemia in transgenic mice [61] and overexpression of CK2 α 
in the mammary gland can bring about hyperplasia and dysplasia [62, 63]. Moreover, CSNK2A1 mRNA is 
highly expressed in several tumor types including CCA (Figure 1A), and, across all tumor types, high CSNK2A1 
expression correlates with poor overall survival (Figure 1B). CK2 enzymatic activity is increased in several 
tumor types including breast cancer, prostate cancer, and lung cancer [62, 64-67]. Increased CK2 activity 
results in increased phosphorylation of CK2 target proteins that include a variety of oncoproteins proteins 
and tumor suppressor proteins. Increased phosphorylation of oncoproteins by CK2 can increase their 
activity whilst increased phosphorylation of tumor suppressor proteins can result in their inactivation. For 
example, CK2 mediated phosphorylation of protein kinase B (PKB)/AKT increases its oncoprotein activity 
while CK2 mediated phosphorylation of the phosphatase and tensin homology protein (PTEN) and the 
promyelocytic leukemia protein (PML), reduces their tumor suppressor activity [68-70]. These, and other 
related observations, led to the suggestion that the inhibition of CK2 activity could be useful in cancer therapy 
as well as in numerous other disease states linked to dysregulated cell proliferation [41, 71]. Our work has 
shown that CK2 phosphorylation of the PRH/HHEX transcription factor prevents this protein from binding 
to DNA and blocks the tumor suppressor activity of this protein in leukemic cells [66, 72, 73]. However, the 
PRH/HHEX gene that encodes PRH is a member of a select group of genes known as proto-oncogenes with 
tumor suppressor function [74]. PRH is not expressed in normal bile duct epithelial cells but it is expressed 
in CCA cells and this context, it acts as an oncoprotein [40]. Further work is required to determine whether 
phosphorylation of PRH occurs in CCA cells and whether this down-regulates PRH activity.
CK2 inhibitors
A variety of CK2 inhibitors have been characterized in different degrees of detail and recent 
comprehensive reviews are available [71, 75, 76]. Many of these inhibitors bind to the ATP/GTP binding 
site and act as competitive inhibitors of CK2. Although several of these competitive inhibitors including 
4,5,6,7-tetrabromobenzotriazole (TBB) and 4,5,6,7-tetrabromo-N,N-dimethyl-1H-benzimidazol-2-amine (DMAT) 
are useful experimental tools, most are unsuitable for clinical use. However, CX-4945 (also known 
as silmitasertib) is a competitive inhibitor that is orally administered and highly specific and this 
drug is currently under investigation in a number of clinical trials [43, 77]. Other CK2 inhibitors act 
independently of the ATP/GTP pocket. For example, CIGB-300 blocks substrate phosphorylation by 
binding to the phosphoacceptor domain of CK2 substrates as well as inhibiting CK2 activity by binding 
directly to CK2 [78, 79]. CIGB-300 is also being investigated in clinical trials and appears to be safe and 
well-tolerated [80, 81]. Allosteric inhibitors that bind away from the active site and block CK2 activity, and 
bi-substrate inhibitors, that compete with ATP and bind to the phosphoacceptor substrate-binding site, are 
also being developed but are not yet in clinical trials [82, 83]. Perhaps most interesting are multi-target 
inhibitors that combine CK2 inhibitors such as CX-4945 with other drugs such as DNA damage-inducing 
cisplatin [84, 85].
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Figure 1. High CSNK2A1 mRNA expression is associated with reduced overall survival across cancer types. (A) Box plot of 
CSNK2A1 mRNA expression levels in multiple cancer types. In each case tumor samples are in red and normal samples are in 
black. Only tumor types with a statistically significant difference in expression between cancer and control samples (P < 0.01) 
are shown. TPM: transcripts per million; CHOL: cholangiocarcinoma; DLBC: diffuse large B-cell lymphoma; ESCA: esophageal 
carcinoma; GBM: glioblastoma multiforme; LGG: lower grade glioma; LUSC: lung squamous cell carcinoma; OV: ovarian serous 
cystadenocarcinoma; PAAD: pancreatic adenocarcinoma; READ: rectum adenocarcinoma; STAD: stomach adenocarcinoma; 
THYM: thymoma; (B) Kaplan-Meier survival analysis of mRNA expression versus overall survival for CSNK2A1, CSNK2A2, and 
CSNK2B (with E2F1 shown for comparison) across all TCGA cancer types. In each case, low expression is shown in blue and 
high expression is shown in red. High CSNK2A1, high CSNK2B, and high E2F1 expression are all associated with reduced overall 
survival. All data were obtained using GEPIA2 from TCGA data sets. E2F1: E2F transcription factor 1; GEPIA2: gene expression 
profiling interactive analysis 2
CK2 in CCA
The genes encoding CK2 subunits (CSNK2A1, CSNK2A2, or CSNK2B) are not mutated in CCA. However, the 
expression of these genes is increased in CCA cells compared to matched normal liver tissue, and the CK2 
α, CK2 α’, and CK2 β proteins are all highly expressed in CCA cell lines [86]. Over-expression of the CK α 
subunits in CCA cells is consistent with the pro-tumourigenic roles of these proteins in other contexts. 
However, the over-expression of CK2 β is in contrast to the generally anti-tumourigenic view of this protein 
gained from studies of other cell types. Importantly, the inhibition of CK2 has been shown to reduce the 
viability of CCA cells in vitro [87, 88] and to reduce the growth of CCA cells in a xenograft mouse model [88]. 
The increased activity of CK2 seen in CCA makes this enzyme an attractive therapeutic target, especially in 
tumors that lack actionable mutations. Moreover, a clinical trial using CX-4945 in combination with cisplatin 
and gemcitabine (ClinicalTrials.gov identifier: NCT02128282) has reported promising preliminary data [89]. 
Here we will outline the effects of CK2 inhibition on CCA cells, alone or in combination with other drugs, and 
discuss the potential for this approach in the treatment of this disease.
CK2 inhibition reduces CCA cell proliferation and cell invasion
Treatment of CCA cell lines with CX-4945 reduces the growth of the cell population over time [87]. 
5-bromo-2’-deoxyuridine (BrdU) incorporation assays show reduced cell proliferation in the presence of 
CX-4945 [87]. Treatment with CX-4945 also increases cell death. Interestingly, CX-4945 treatment appears to 
induce two forms of programmed cell death, methuosis, and apoptosis, as discussed in detail below.
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Treatment with 10 μmol/L CX-4945 also reduces CCA cell migration and reduces the ability of these 
cells to invade Matrigel [87], and extracellular matrix that models the basement membrane that surrounds 
epithelial tissues. This appears to be a direct consequence of CK2 inhibition by CX-4945 since the combined 
knockdown of CK2 α and CK2 α’ expression using small interfering RNA (siRNA) also inhibits cell invasion [87]. 
Interestingly, lower doses of CX-4945 appear to increase cell invasion possibly due to increased expression 
of matrix metallopeptidases [87]. Any stimulatory effects of low doses of CX-4945 on cell invasion could have 
negative consequences in clinical applications.
CK2 inhibitors can induce apoptosis and methuosis in CCA cells
Apoptosis is a form of programmed cell death that involves chromatin compaction, DNA fragmentation, 
cytoplasmic blebbing/boiling, and cell shrinkage [90]. In contrast, methuosis is a form of cell death 
characterized by the presence of large vacuoles that derive from macropinosomes, in the absence of cell 
shrinkage and chromatin compaction [91]. Treatment of CCA cells with the CK2 inhibitor CX-4945 can induce 
both apoptosis and methuosis. Apoptosis is induced by CX-4945 ≥ 10 μmol/L although only after relatively 
long treatments of 48 h or 72 h [88]. In contrast, treatment with 10 μmol/L CX-4945 can induce methuosis 
after just a few hours and this form of cell death is even more pronounced with higher doses [87]. This 
suggests that the reduction of CCA cell viability following CX-4945 treatment arises from an early effect on 
methuosis combined with a longer-term effect on apoptosis. Interestingly, the induction of methuosis does 
not appear to be due to the effects of CX-4945 on CK2 since the removal of the CK2 protein using siRNA 
does not prevent CX-4945-induced methuosis [87]. Moreover, although CX-4945 and the closely related 
drug CX-5011 induced vacuolization in HepG2 cells, other inhibitors of CK2 including TBB, failed to induce 
vacuolization [92]. The Rac1 GTPase plays a central role in growth factor signaling via Ras activation and 
other signaling pathways and is important in methuosis [91]. Recent elegant experiments have shown that 
the inhibition of Rac1 activity or Rac1 knockdown using siRNA, significantly reduces the effects of CX-5011 
on vacuolization [92]. Moreover, CX-5011 treatment results in Rac1 activation [92]. The effects of different 
CK2 inhibitors on methuosis and apoptosis are summarized in Figure 2. The activation of Rac1 by these CK2 
inhibitors could also be important in the effects of these drugs on cell migration and invasion. Moreover, 
CX-4945 and CX-5011 have other off-target effects including the alteration of mRNA splicing through the 
inhibition of Cdc2-like kinases [93], and these off-target effects could also be in part responsible for CX-4945/
CX-5011-induced methuosis.
Figure 2. CK2 inhibitors induce cell death by multiple mechanisms. A schematic representation of the effects of CK2 inhibitors on 
cell fate. Methuosis is a rapid response to some CK2 inhibitors occurring within a few hours. Apoptosis is a slower response to 
CK2 inhibition occurring after 24 h or more. CK2 inhibition in conjunction with chemotherapeutic drugs that induce DNA damage 
results in increased levels of cell death and this may be useful in cancer treatment
Drug combinations
The combination of CX-4945 with drugs that block AKT activity or TGF β signaling results in an additive 
inhibitory effect on CCA cells in vitro [94]. Similarly, loss of CK2 α activity by CRISPR/Cas9 genome editing 
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increases the inhibitory effects of 5-fluorouracil or gemcitabine on the viability of CCA cells [86]. As might be 
expected, the combination of CX-4945 with either cisplatin or gemcitabine results in increased cytotoxicity 
against CCA cell lines [88]. The combination of CX-4945 with these drugs has an additive inhibitory effect 
on cell viability (Figure 2). Importantly, the triple combination of CX-4945 with cisplatin and gemcitabine 
reduced the growth of CCA tumors in a xenograft mouse model [88].
The sequence of drug administration is often of importance when drugs are combined. Administration 
of a drug that blocks the repair of DNA damage followed by the addition of a drug that induces DNA damage 
might logically be expected to be more efficacious than the reverse combination. However, this is not the 
case since treatment of ovarian cancer cell lines with cisplatin or gemcitabine prior to CX-4945 treatment 
resulted in more cell death compared to the reverse sequence of drug additions [60]. This drug combination 
is the subject of ongoing clinical trials which propose to treat patients with CX-4945 prior to cisplatin 
treatment. However, treatment with cisplatin prior to CX-4945 treatment may be of greater efficacy. The use 
of multi-target inhibitors, such as Cx-platin which combines CX-4945 and cisplatin to inhibit CK2 and induce 
DNA damage [84], might also be more effective in blocking the growth of CCA tumors.
Conclusions
The inhibition of CK2 activity could be of value in the treatment of CCA most likely in combination with 
drugs that induce DNA damage. CK2 expression of CK2 activity in CCA could be used to select patients with 
tumors that might respond well to these approaches. However, further work is required to establish the most 
efficacious drug combinations and identify patients who will benefit from this approach. This approach may 
be particularly useful for the treatment of tumors that lack actionable mutations or are resistant to targeted 
treatments. In the context of many countries with a high incidence of CCA, targeted therapies are unlikely to 
be widely available in the foreseeable future due to resource limitations. Combination therapies that make 
use of CK2 inhibitors may provide treatment options that are both efficacious and cost-effective. Local clinical 
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